Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > BTD+AA with Quarterly Release this week?
View:
Post by N0taP00p on Nov 25, 2024 12:38pm

BTD+AA with Quarterly Release this week?

They don't seem to be casting their net wide for funds ie. just enough to survive a month or two each time, probably from the same set of investors who've drunk the science Kool-Aid like many of us.    By now, they should be close to receiving a yes or no on BTD.  If the FTD designation has been used effectively, the FDA should already know everything they need to know, given the pre-BTD Q&A that happened recently with senior FDA folks.   Let's hope they get it in time for the quarterly release.   If on the other hand, the FDA asks for more data,  we might be dealing with a new FDA team by mid next year.
Comment by rhodiumd on Nov 25, 2024 12:51pm
No. BTD approval should under no circumstances be "diluted" alongside other news or announcements. It should be a standalone NR. Period.
Comment by menoalittle on Nov 25, 2024 2:07pm
BTD application is newsworthy enough to be a stand alone announcement, say nothing about approval... which would definitely deserve a trading halt.
Comment by Kayz88 on Nov 25, 2024 1:54pm
I think the quarterly earnings report contain a snippet that says "We submitted the BTD application to the FDA for approval on Insert Date " Now we wait for news of approval. I doubt that they'll let us know they got approval along side a quarterly report, timing doesn't make sense. The FDA has 60 days to respond to the BTD submission. 
Comment by menoalittle on Nov 25, 2024 2:04pm
I think you're full of baloney
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250